Hidradenitis

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

Retrieved on: 
Sunday, October 15, 2023

We have consistently observed best-in-class clinical activity with our Nanobody®sonelokimab for hidradenitis suppurativa and these results demonstrate its effect on a number of clinically meaningful endpoints.

Key Points: 
  • We have consistently observed best-in-class clinical activity with our Nanobody®sonelokimab for hidradenitis suppurativa and these results demonstrate its effect on a number of clinically meaningful endpoints.
  • In June we elevated the bar for clinical response to HiSCR75 as the primary endpoint.
  • The MIRA trial set a landmark milestone as the first placebo-controlled randomized trial in HS to use Hidradenitis Suppurative Clinical Response 75 (HiSCR75) as the primary endpoint.
  • The 24-week results show that ongoing treatment with sonelokimab 120mg and 240mg dosed Q4W, further increased HiSCR75 response rates compared to week 12.

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Retrieved on: 
Thursday, October 12, 2023

There is a compelling need for new treatment options that can offer high and durable clinical response," said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB.

Key Points: 
  • There is a compelling need for new treatment options that can offer high and durable clinical response," said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB.
  • "Data presented at EADV showed that over 48 weeks many patients treated with bimekizumab achieved high thresholds of response.
  • These findings suggest that inhibition of IL-17F in addition to IL-17A represents a promising treatment approach in moderate-to-severe hidradenitis suppurativa."
  • "The bimekizumab Phase 3 clinical trial program in hidradenitis suppurativa included the more stringent clinical outcomes of HiSCR75, HiSCR90 and HiSCR100 in addition to the standard HiSCR50.

2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023

The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Key Points: 
  • The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Among the EU-5 countries, Germany accounted for the highest number of Hidradenitis Suppurativa cases, whereas Spain accounted for the lowest cases in 2021.
  • A detailed review of Hidradenitis Suppurativa epidemiology forecast is included in the report, covering the 7MM drug outreach.
  • The Hidradenitis Suppurativa Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies.

United States Hidradenitis Suppurativa Market and Competitive Landscape Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 9, 2022

The "US Hidradenitis Suppurativa Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Hidradenitis Suppurativa Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive insights into Hidradenitis Suppurativa pipeline products, Hidradenitis Suppurativa epidemiology, Hidradenitis Suppurativa market valuations and forecast, Hidradenitis Suppurativa drugs sales and competitive landscape in the US.
  • Hidradenitis Suppurativa pipeline: Find out the products in clinical trials for the treatment of Hidradenitis Suppurativa by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Hidradenitis Suppurativa drugs: Identify key products marketed and prescribed for Hidradenitis Suppurativa in the US, including trade name, molecule name, and company
    Hidradenitis Suppurativa market valuations: Find out the market size for Hidradenitis Suppurativa drugs in 2021 in the US.
  • Find out how the market advanced from 2019 and forecast to 2027
    Hidradenitis Suppurativa drugs market share: Find out the market shares for key Hidradenitis Suppurativa drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Hidradenitis Suppurativa products

AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

Retrieved on: 
Wednesday, August 31, 2022

Imsidolimab previously demonstrated efficacy and safety in the GALLOP Phase 2 trial in generalized pustular psoriasis (GPP), a systemic, life-threatening inflammatory disease in which imsidolimab has been granted Orphan Disease Designation.

Key Points: 
  • Imsidolimab previously demonstrated efficacy and safety in the GALLOP Phase 2 trial in generalized pustular psoriasis (GPP), a systemic, life-threatening inflammatory disease in which imsidolimab has been granted Orphan Disease Designation.
  • Enrollment of the GEMINI-1 GPP Phase 3 registrational trial is ongoing and top-line data is anticipated in Q4 2023.
  • This double-blind, placebo-controlled Phase 2 trial enrolled 149 patients, at sites located within North America and Europe, with moderate to severe hidradenitis suppurativa.
  • Serious TEAEs were observed in 6.1% (n=3) of placebo patients vs. 4.0 % (n=2) on imsidolimab low dose and 0 in the imsidolimab high dose.